Site Map

Home
How Novel CELMoD Agents Work
Clinical Trials
Clinical Trial Eligibility Tool
Clinical Trial Location Finder

Contact Us
Privacy Policy

Legal Notice
Site Map

This website is for US physicians to provide general information about ongoing BMS clinical trials and as an exchange of scientific information related to BMS investigational products iberdomide and mezigdomide. Iberdomide and mezigdomide are not currently approved in any market and have not been evaluated by the FDA as safe or effective for multiple myeloma.

© 2024 Bristol Myers Squibb Company. All rights reserved.

HE-US-2300633 1/24

Please verify that you are a US Healthcare Professional

This information is intended for US Healthcare Professionals

I am a US Healthcare Professional

I am not a US Healthcare Professional

You are about to leave this Bristol Myers Squibb website. You are being redirected to another Bristol Myers Squibb website.

Would you like to leave the website?

You are now leaving this Bristol Myers Squibb website.

You are about to leave this website for another external website. Bristol Myers Squibb has no responsibility for the content of such other sites and is not liable for any damages or injury arising from that content. Any links to other sites are provided merely as a convenience to the users of this website.